b'/msfocusThe Tolebrutinib Trials Find Out If You QualifyActively Recruiting for Phase III Multiple Sclerosis Clinical Trials The primary objective of theseTrial-related Phase III Trials is to compare themedication and average number of relapses per year between two treatment groups,medical care may be study drug vs. placebo.provided at no charge to patients who qualify. If travel is required, all travel See site for details, visit: related costs are reimbursed www.mymstrials.com/msfocus including meals, hotel, transportation, and even airfare.Online pre-qualication is private, and takes about 30 seconds.See site for details, including more information about Tolebrutinibs Phase IITolebrutinib, and to learn more about MS Clinical Trial ResultsClinical Trial participation. Summary:In completed phase II study, 130 participants with relapsing-remitting MSwww.mymstrials.com/msfocustook one of 4 doses of tolebrutinib for 12 weeks either before or after taking placebo for 4 weeks.Compared to the placebo period treatment with the highest dose of tolebmtinib (sameTolebrutinib is experimental, not yet as used in current clinical trials) resulted inapproved by health authorities, and 85% to 89% relative reduction in new MS brain lesions. is still under investigation for the treatment of MS. The most frequently reported side effects in the phase II clinical bid were headaches and u-like symptoms.The Tolebrutinib Trials are sponsored by Sano.'